Ra Pharmaceuticals (NASDAQ:RARX) Upgraded to “Sell” at BidaskClub

BidaskClub upgraded shares of Ra Pharmaceuticals (NASDAQ:RARX) from a strong sell rating to a sell rating in a report issued on Wednesday morning, BidAskClub reports.

A number of other research firms have also issued reports on RARX. SunTrust Banks lowered shares of Ra Pharmaceuticals from a buy rating to a hold rating in a research note on Monday, October 14th. Jefferies Financial Group lowered shares of Ra Pharmaceuticals from a buy rating to a hold rating and set a $48.00 price objective for the company. in a research report on Thursday, October 10th. BMO Capital Markets cut shares of Ra Pharmaceuticals from an outperform rating to a market perform rating and set a $48.00 price objective on the stock. in a research note on Thursday, October 10th. Royal Bank of Canada reiterated a sector perform rating and issued a $48.00 target price on shares of Ra Pharmaceuticals in a report on Friday, October 11th. Finally, Credit Suisse Group lowered shares of Ra Pharmaceuticals from an outperform rating to a neutral rating in a research note on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating and thirteen have given a hold rating to the company’s stock. Ra Pharmaceuticals currently has a consensus rating of Hold and a consensus price target of $45.36.

NASDAQ RARX traded up $0.12 during trading hours on Wednesday, hitting $46.99. The company had a trading volume of 246,825 shares, compared to its average volume of 645,380. The company has a quick ratio of 25.73, a current ratio of 25.73 and a debt-to-equity ratio of 0.01. The firm has a market cap of $2.20 billion, a P/E ratio of -22.81 and a beta of 1.50. Ra Pharmaceuticals has a fifty-two week low of $14.50 and a fifty-two week high of $47.35. The business has a fifty day simple moving average of $46.70 and a 200-day simple moving average of $32.69.

Ra Pharmaceuticals (NASDAQ:RARX) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.05). The firm had revenue of $3.00 million for the quarter. Equities analysts forecast that Ra Pharmaceuticals will post -2.05 EPS for the current fiscal year.

In other news, insider Simon Read sold 10,000 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $25.41, for a total value of $254,100.00. Following the completion of the sale, the insider now owns 16,234 shares in the company, valued at $412,505.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ramin Farzaneh-Far sold 10,595 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $25.26, for a total value of $267,629.70. Following the completion of the sale, the insider now owns 8,521 shares of the company’s stock, valued at approximately $215,240.46. The disclosure for this sale can be found here. Over the last quarter, insiders sold 44,070 shares of company stock valued at $1,619,601. Corporate insiders own 4.30% of the company’s stock.

Several hedge funds have recently modified their holdings of RARX. Marshall Wace LLP acquired a new position in Ra Pharmaceuticals during the first quarter valued at $229,000. FMR LLC increased its holdings in Ra Pharmaceuticals by 12.9% during the 1st quarter. FMR LLC now owns 466,834 shares of the company’s stock worth $10,457,000 after purchasing an additional 53,445 shares in the last quarter. Virginia Retirement Systems ET AL raised its stake in shares of Ra Pharmaceuticals by 12.9% in the second quarter. Virginia Retirement Systems ET AL now owns 10,500 shares of the company’s stock worth $316,000 after purchasing an additional 1,200 shares during the last quarter. Moody Aldrich Partners LLC raised its stake in shares of Ra Pharmaceuticals by 2.8% in the second quarter. Moody Aldrich Partners LLC now owns 41,039 shares of the company’s stock worth $1,234,000 after purchasing an additional 1,134 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its holdings in shares of Ra Pharmaceuticals by 15.0% in the second quarter. Candriam Luxembourg S.C.A. now owns 1,178,000 shares of the company’s stock valued at $35,267,000 after purchasing an additional 154,000 shares in the last quarter.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Further Reading: Gap Up Stocks

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.